324 related articles for article (PubMed ID: 16946454)
21. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Hirsch MS; Brun-Vézinet F; Clotet B; Conway B; Kuritzkes DR; D'Aquila RT; Demeter LM; Hammer SM; Johnson VA; Loveday C; Mellors JW; Jacobsen DM; Richman DD
Clin Infect Dis; 2003 Jul; 37(1):113-28. PubMed ID: 12830416
[TBL] [Abstract][Full Text] [Related]
22. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
[TBL] [Abstract][Full Text] [Related]
23. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
24. Antiretroviral resistance testing for clinical management.
Youree BE; D'Aquila RT
AIDS Rev; 2002; 4(1):3-12. PubMed ID: 11998782
[TBL] [Abstract][Full Text] [Related]
25. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
26. Treatment of heavily antiretroviral-experienced HIV-infected patients.
Lunzen Jv
AIDS Rev; 2007; 9(4):246-53. PubMed ID: 18219368
[TBL] [Abstract][Full Text] [Related]
27. Incorporating novel virologic tests into clinical practice.
Daar ES
Top HIV Med; 2007; 15(4):126-9. PubMed ID: 17720997
[TBL] [Abstract][Full Text] [Related]
28. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C
J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
[TBL] [Abstract][Full Text] [Related]
30. Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy.
Schmidt B; Walter H; Zeitler N; Korn K
AIDS Rev; 2002; 4(3):148-56. PubMed ID: 12416449
[TBL] [Abstract][Full Text] [Related]
31. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
32. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
33. Developments in HIV treatments: strategies for success.
Piliero P
AIDS Read; 2004 Dec; 14(12):655-65. PubMed ID: 15619781
[TBL] [Abstract][Full Text] [Related]
34. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
[TBL] [Abstract][Full Text] [Related]
35. New drugs for old.
Winston A; Stebbing J
J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
Holguín A; Ramirez de Arellano E; Rivas P; Soriano V
AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277
[TBL] [Abstract][Full Text] [Related]
37. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings.
Lynen L; Van Griensven J; Elliott J
Curr Opin HIV AIDS; 2010 Jan; 5(1):1-5. PubMed ID: 20046141
[TBL] [Abstract][Full Text] [Related]
38. Structured treatment interruptions--new findings.
Benson CA
Top HIV Med; 2006; 14(3):107-11. PubMed ID: 16946455
[TBL] [Abstract][Full Text] [Related]
39. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
[TBL] [Abstract][Full Text] [Related]
40. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010.
Gilleece Y; Chadwick DR; Breuer J; Hawkins D; Smit E; McCrae LX; Pillay D; Smith N; Anderson J;
HIV Med; 2010 Nov; 11(10):611-9. PubMed ID: 20961377
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
